Fda Commissioner Stephen Hahn on the Fda’s Emergency Use Authorization of Convalescent Plasma as a Treatment for Hospitalized Covid–19 Patients.

August 23, 2020
Featured article image

This is a major advance in the treatment of patients.

  • Convalescent plasma has been used to treat a range of infections/diseases in the past. Convalescent plasma COVID-19 treatment involves giving a patient the blood plasma from someone with the same blood type who has already recovered from COVID-19.
  • The FDA made the announcement, citing early promising data from over 70,000 American patients, saying the known and potential benefits outweigh the known and potential risks.
    • Health and Human Services Secretary Alex Azar said they’ve seen a 35% mortality reduction in the patients who have benefited the most from convalescent plasma – all of whom were under 80 and not receiving artificial respiration.
  • Why It Matters: The FDA’s emergency use authorization opens up the possibility for quicker and easier access to the treatment *as* convalescent plasma studies and clinical trials continue.
    • Officials urge those who have recovered from COVID-19 to donate plasma. Learn about how to donate HERE

Context: Just recently several former FDA commissioners came out in support of this treatment: CLICK HERE

QUICK VIDEO on the research on blood & COVID-19 ~ Plus ~ what convalescent plasma is all about: WHAT’S BLOOD GOT TO DO WITH IT?

by Jenna Lee,